Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.

[1]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[2]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[3]  Akshay S. Desai,et al.  Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2019, JAMA.

[4]  S. Solomon,et al.  Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. , 2019, JAMA.

[5]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[6]  S. Solomon,et al.  Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. , 2019, JACC. Heart failure.

[7]  E. Braunwald,et al.  Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial , 2019, European heart journal.

[8]  Akshay S. Desai,et al.  Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. , 2019, Circulation.

[9]  S. Yun,et al.  Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study , 2019, Circulation.

[10]  J. Felius,et al.  EFFECT OF PREOPERATIVE RENAL DYSFUNCTION ON COST AND OUTCOMES IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFT IN THE UNITED STATES BETWEEN 2004-2014 , 2019, Journal of the American College of Cardiology.

[11]  F. Apple,et al.  Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. , 2019, Journal of the American College of Cardiology.

[12]  Akshay S. Desai,et al.  B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. , 2019, Journal of the American College of Cardiology.

[13]  Akshay S. Desai,et al.  Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial , 2019, European journal of heart failure.

[14]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[15]  S. Solomon,et al.  Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. , 2019, Journal of the American College of Cardiology.

[16]  A. Cohen-Solal,et al.  Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study , 2018, European journal of heart failure.

[17]  Akshay S. Desai,et al.  Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial , 2018, JAMA cardiology.

[18]  R. Wachter,et al.  Sacubitril/Valsartan Initiated in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction after Hemodynamic Stabilization: Primary Results of the TRANSITION Study , 2018, Journal of Cardiac Failure.

[19]  M. Senni,et al.  Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. , 2018, International journal of cardiology.

[20]  S. Solomon,et al.  Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. , 2018, The lancet. Diabetes & endocrinology.

[21]  P. Vandervoort,et al.  The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction , 2018, Cardiovascular therapeutics.

[22]  Akshay S. Desai,et al.  Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial , 2018, JAMA cardiology.

[23]  S. Solomon,et al.  Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE‐HF) , 2018, American heart journal.

[24]  H. Krum,et al.  Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. , 2018, International journal of cardiology.

[25]  Akshay S. Desai,et al.  Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. , 2018, JACC. Heart failure.

[26]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) , 2018, European journal of heart failure.

[27]  S. Solomon,et al.  P3373Better health-related quality of life in patients treated with sacubitril/valsartan compared with enalapril, irrespective of NYHA class: Analysis of EQ-5D in PARADIGM-HF , 2017 .

[28]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.

[29]  S. Solomon,et al.  Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction , 2016, European journal of heart failure.

[30]  Akshay S. Desai,et al.  Health-Related Quality of Life Outcomes in PARADIGM-HF , 2017, Circulation. Heart failure.

[31]  Akshay S. Desai,et al.  Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial , 2017, JAMA cardiology.

[32]  G. Fonarow,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Circulation.

[33]  S. Zraika,et al.  Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels , 2017, Diabetologia.

[34]  Akshay S. Desai,et al.  Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. , 2016, Journal of the American College of Cardiology.

[35]  Akshay S. Desai,et al.  Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. , 2016, JACC. Heart failure.

[36]  S. Solomon,et al.  Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy , 2016, Circulation. Heart failure.

[37]  Akshay S. Desai,et al.  Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. , 2016, Journal of the American College of Cardiology.

[38]  S. Solomon,et al.  Geographic variations in the PARADIGM-HF heart failure trial , 2016, European heart journal.

[39]  Akshay S. Desai,et al.  Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial , 2016, European journal of heart failure.

[40]  Akshay S. Desai,et al.  Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial , 2016, Circulation. Heart failure.

[41]  R. Wachter,et al.  Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens , 2016, European journal of heart failure.

[42]  N. Brown,et al.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition , 2016, Circulation.

[43]  Akshay S. Desai,et al.  Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. , 2016, Circulation. Heart failure.

[44]  S. Solomon,et al.  Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. , 2015, The New England journal of medicine.

[45]  Akshay S. Desai,et al.  Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. , 2015, Journal of the American College of Cardiology.

[46]  Akshay S. Desai,et al.  Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. , 2015, European heart journal.

[47]  Akshay S. Desai,et al.  Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF , 2015, European heart journal.

[48]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.

[49]  D. Atar,et al.  Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy , 2015, Circulation. Heart failure.

[50]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[51]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[52]  C. Yancy,et al.  Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. , 2011, American heart journal.

[53]  Ayan R Patel,et al.  Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. , 2011, JACC. Cardiovascular imaging.

[54]  A. Struthers,et al.  Interactions between atrial natriuretic factor and the autonomic nervous system , 1991, Clinical Autonomic Research.

[55]  H. Black,et al.  Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. , 2004, American journal of hypertension.